JDD Buzz Series | Social Media’s Impact on Hair Loss Information
Social media is a major source of medical information, including information about hair loss. How reliable is the hair loss material presented on social media, and how does this information impact patients? Those are some of the questions posed by researchers in a study published in the March Journal of Drugs in Dermatology.
I interviewed author Raymond Ezzat, third-year medical student at Geor …
Social media is a major source of medical information, including information about hair loss. How reliable is the hair loss material presented on social media, and how does this information impact patients? Those are some of the questions posed by researchers in a study published in the March Journal of Drugs in Dermatology.
I interviewed author Raymond Ezzat, third-year medical student at Geor … Continue reading "JDD Buzz Series | Social Media’s Impact on Hair Loss Information"
Get ready to explore the latest advancements in dermatology with the March issue of the Journal of Drugs in Dermatology! This edition dives deep into cutting-edge research, including AI-driven personalized hair loss treatments, the dermatologic potential of berberine, and the evolving role of social media in hair loss education. Plus, don't miss insights on acneceuticals, the skin microbiome in ec … 
[vc_row][vc_column][vc_column_text css=""]Despite decades of educational efforts, there is growing public skepticism over sunscreen’s safety and efficacy. Researchers from Chicago sought to synthesize the current scientific understanding of sunscreen in order to help dermatology clinicians address concerns. The findings are published in the February Journal of Drugs in Dermatology.
I intervie … 
The February 2025 issue of the Journal of Drugs in Dermatology brings a fresh wave of clinical insights and innovative research to the dermatology community. This edition highlights new perspectives on minoxidil adherence, groundbreaking findings in keloid and hypertrophic scar risk factors, and expert consensus on deucravacitinib for plaque psoriasis.
Readers will also discover updates on non- … 
Underrepresentation of patients with skin of color in clinical trials is an issue in medical research, including in research about dermatological conditions. A study in the January Journal of Drugs in Dermatology looked at the diversity of patients enrolled in melasma clinical trials to determine if there are any disparities in representation.
I interviewed author Jared Jagdeo, MD, MS, associat … 